Additionally, the oncogene MYC, associated with various cancer types, influences drug sensitivity in CML and aids in the survival of CML CD34+ leukemic stem cells [45]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.